DoH Policies screened during the period – 1 July 2026 – 30 September 2026
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- 5 Moments for Medication Safety: Patient Safety Toolkit
- Equality Screening for the consultation on options to restrict or stop the routine prescribing of selected medicines in primary care
- NICE Technology Appraisal TA1045 - 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) (update)
- NICE Technology Appraisal TA1087 - 12 SQ-Bet SLIT for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen in people 5 years and over
- NICE Technology Appraisal TA1174 - Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy
- NICE Technology Appraisal TA1175 - Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis
- NICE Technology Appraisal TA1176 - Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes
- NICE Technology Appraisal TA1178 - Deuruxolitinib for treating severe alopecia areata
- NICE Technology Appraisal TA1181 - Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy
- NICE Technology Appraisal TA1182 - Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
- NICE Technology Appraisal TA1183 - Donidalorsen for preventing recurrent attacks of hereditary angiodema in people 12 years and over
- NICE Technology Appraisal TA1184 - Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma
- NICE Technology Appraisal TA1185 - Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronioc lymphocytic leukaemia
- NICE Technology Appraisal TA1189 - Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
- The Provision of Health Services to Persons Not Ordinarily Resident (Amendment) Regulations (Northern Ireland) 2026